215 related articles for article (PubMed ID: 19297270)
1. Difference in killing activity of caspofungin and paradoxical growth between Candida albicans and C. krusei clinical isolates in different media.
Varga I; Sóczó G; Kardos G; Kemény-Beke A; Kelentey B; Márton I; Majoros L
J Chemother; 2009 Feb; 21(1):36-41. PubMed ID: 19297270
[TBL] [Abstract][Full Text] [Related]
2. Time-kill studies investigating the killing activity of caspofungin against Candida dubliniensis: comparing RPMI-1640 and antibiotic medium 3.
Varga I; Sóczó G; Kardos G; Majoros L
J Antimicrob Chemother; 2008 Jul; 62(1):149-52. PubMed ID: 18390882
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.
Desnos-Ollivier M; Bretagne S; Raoux D; Hoinard D; Dromer F; Dannaoui E;
Antimicrob Agents Chemother; 2008 Sep; 52(9):3092-8. PubMed ID: 18591282
[TBL] [Abstract][Full Text] [Related]
4. [The fungicidal activity and paradoxical effect of caspofungin against yeast. Influence of culture medium and incubation time].
Cantón E; Pemán J; Romero M; Valentín A; Gobernado M
Rev Esp Quimioter; 2007 Dec; 20(4):433-41. PubMed ID: 18563217
[TBL] [Abstract][Full Text] [Related]
5. Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum.
Kovács R; Saleh Q; Bozó A; Tóth Z; Gesztelyi R; Kardos T; Kardos G; Takacs I; Majoros L
Mycopathologia; 2017 Dec; 182(11-12):979-987. PubMed ID: 28699056
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Sensititre Yeast One microdilution method for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin.
García-Agudo L; García-Martos P; Martos-Cañadas J; Aznar-Marín P; Marín-Casanova P; Rodríguez-Iglesias M
Rev Esp Quimioter; 2012 Dec; 25(4):256-60. PubMed ID: 23303256
[TBL] [Abstract][Full Text] [Related]
7. Killing Rates of Caspofungin in 50 Percent Serum Correlate with Caspofungin Efficacy Against Candida albicans in a Neutropenic Murine Model.
Domán M; Kovács R; Kardos G; Gesztelyi R; Juhász B; Bozó A; Kardos T; Saleh Q; Majoros L
Curr Drug Deliv; 2016; 13(2):255-64. PubMed ID: 27146910
[TBL] [Abstract][Full Text] [Related]
8. Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum.
Kovács R; Gesztelyi R; Perlin DS; Kardos G; Domán M; Berényi R; Majoros L
Mycopathologia; 2014 Oct; 178(3-4):197-206. PubMed ID: 25118874
[TBL] [Abstract][Full Text] [Related]
9. Killing rates exerted by caspofungin in 50 % serum and its correlation with in vivo efficacy in a neutropenic murine model against Candida krusei and Candida inconspicua.
Kovács R; Gesztelyi R; Berényi R; Domán M; Kardos G; Juhász B; Majoros L
J Med Microbiol; 2014 Feb; 63(Pt 2):186-194. PubMed ID: 24184471
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans.
Nussbaumer-Pröll A; Matzneller P; Eberl S; Zeitlinger M
Eur J Clin Microbiol Infect Dis; 2024 May; 43(5):927-936. PubMed ID: 38483681
[TBL] [Abstract][Full Text] [Related]
11. SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.
Scorneaux B; Angulo D; Borroto-Esoda K; Ghannoum M; Peel M; Wring S
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069658
[TBL] [Abstract][Full Text] [Related]
12. Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology.
Szilágyi J; Földi R; Bayegan S; Kardos G; Majoros L
J Chemother; 2012 Feb; 24(1):18-25. PubMed ID: 22546720
[TBL] [Abstract][Full Text] [Related]
13. Examination of the in vitro fungicidal activity of echinocandins against Candida lusitaniae by time-killing methods.
Cantón E; Pemán J; Hervás D; Espinel-Ingroff A
J Antimicrob Chemother; 2013 Apr; 68(4):864-8. PubMed ID: 23228935
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.
Clancy CJ; Huang H; Cheng S; Derendorf H; Nguyen MH
Antimicrob Agents Chemother; 2006 Jul; 50(7):2569-72. PubMed ID: 16801448
[TBL] [Abstract][Full Text] [Related]
15. Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time-kill methodology.
Földi R; Szilágyi J; Kardos G; Berényi R; Kovács R; Majoros L
Diagn Microbiol Infect Dis; 2012 Aug; 73(4):338-42. PubMed ID: 22726529
[TBL] [Abstract][Full Text] [Related]
16. Five-minute exposure to caspofungin results in prolonged postantifungal effects and eliminates the paradoxical growth of Candida albicans.
Shields RK; Nguyen MH; Press EG; Clancy CJ
Antimicrob Agents Chemother; 2011 Jul; 55(7):3598-602. PubMed ID: 21537017
[TBL] [Abstract][Full Text] [Related]
17. Postantifungal effect of caspofungin against the Candida albicans and Candida parapsilosis clades.
Gil-Alonso S; Jauregizar N; Eraso E; Quindós G
Diagn Microbiol Infect Dis; 2016 Oct; 86(2):172-7. PubMed ID: 27492134
[TBL] [Abstract][Full Text] [Related]
18. Poor in vivo efficacy of caspofungin, micafungin and amphotericin B against wild-type Candida krusei clinical isolates does not correlate with in vitro susceptibility results.
Kardos T; Kovács R; Kardos G; Varga I; Bozó A; Tóth Z; Nagy F; Majoros L
J Chemother; 2018 Jul; 30(4):233-239. PubMed ID: 30025501
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species.
Pfaller MA; Messer SA; Mills K; Bolmström A; Jones RN
J Clin Microbiol; 2001 Dec; 39(12):4387-9. PubMed ID: 11724849
[TBL] [Abstract][Full Text] [Related]
20. Identification of the paradoxical effect of caspofungin and micafungin on
Zhouying H; Chen L; Ruiqi W; Kang L; Ji Z
Indian J Med Microbiol; 2017; 35(2):252-255. PubMed ID: 28681815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
